$2.21
10.73% today
Nasdaq, Aug 12, 04:47 pm CET
ISIN
US05280R1005
Symbol
AUTL

Autolus Therapeutics plc Stock price

$2.47
+0.00 0.00% 1M
+0.56 29.32% 6M
+0.12 5.11% YTD
-1.21 32.88% 1Y
-0.99 28.61% 3Y
-12.90 83.93% 5Y
-22.53 90.12% 10Y
-22.53 90.12% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.14 6.01%
ISIN
US05280R1005
Symbol
AUTL
Industry

Key metrics

Basic
Market capitalization
$620.1m
Enterprise Value
$357.0m
Net debt
positive
Cash
$516.6m
Shares outstanding
266.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
68.8 | 10.7
EV/Sales
39.6 | 6.2
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
54.6%
Return on Equity
-51.6%
ROCE
-30.7%
ROIC
-98.8%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$9.0m | $57.9m
EBITDA
$-200.6m | $-231.6m
EBIT
$-208.8m | $-238.7m
Net Income
$-179.9m | $-247.6m
Free Cash Flow
$-283.9m
Growth (TTM | estimate)
Revenue
-14.2% | 472.3%
EBITDA
-19.0% | 0.6%
EBIT
-19.3% | 0.9%
Net Income
18.7% | -12.2%
Free Cash Flow
-87.3%
Margin (TTM | estimate)
Gross
-225.6%
EBITDA
-2,225.8% | -399.8%
EBIT
-2,316.7%
Net
-1,996.0% | -427.5%
Free Cash Flow
-3,150.1%
More
EPS
$-0.7
FCF per Share
$-1.1
Short interest
6.8%
Employees
649
Rev per Employee
$20.0k
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Autolus Therapeutics plc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
94%
Hold
6%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.01 9.01
14% 14%
100%
- Direct Costs 29 29
-
326%
-20 -20
-
-226%
- Selling and Administrative Expenses 91 91
63% 63%
1,005%
- Research and Development Expense 98 98
25% 25%
1,086%
-201 -201
19% 19%
-2,226%
- Depreciation and Amortization 8.19 8.19
27% 27%
91%
EBIT (Operating Income) EBIT -209 -209
19% 19%
-2,317%
Net Profit -180 -180
19% 19%
-1,996%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Neutral
GlobeNewsWire
about 4 hours ago
Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025 Company recently received conditional marketing authorization from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for AUCATZYL® Follow up data from the FELIX trial demonstrating obe-c...
Neutral
GlobeNewsWire
19 days ago
LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 1...
Neutral
GlobeNewsWire
22 days ago
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commer...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 649
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today